Marisa Wexler, MS, senior science writer —

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

Dosing begins in trial of potential therapy for GBA1 Parkinson’s

Dosing has begun in a Phase 1 clinical trial that is testing GT-02287, an experimental oral medication being developed to treat Parkinson’s disease caused by mutations in the GBA1 gene. The first two participants in the trial have been dosed, according to the therapy’s developer, Gain Therapeutics. “Initiating first-in-human…

DDC enzyme may be biomarker of Parkinson’s, related diseases

Measuring levels of an enzyme called DOPA decarboxylase (DDC) in the blood or fluid around the brain and spinal cord may help distinguish Parkinson’s disease and related disorders from non-Parkinsonian neurodegenerative diseases, a study reports. “Since the symptoms of various neurodegenerative brain diseases resemble each other, there is a…

Alpha-synuclein lifts up at cell membranes; may promote clumping

When the alpha-synuclein protein is present at high concentrations around cellular membranes, it lifts up rather than lying flat against the membrane, making it more prone to clumping, a study shows. The finding may offer insight into the molecular mechanisms that drive Parkinson’s disease, where toxic clumps of alpha-synuclein…

Study uncovers previously unknown role of parkin in dopamine signaling

The parkin enzyme — whose loss is a known genetic risk factor of Parkinson’s disease — not only helps to regulate healthy activity of energy-generating mitochondria, but also plays critical roles in nerve cell communication, according to a study using patient-derived neurons. Particularly, parkin loss resulted in defective recycling…

Measuring eye movements may help track Parkinson’s progression

A platform developed by NeuraLight that uses machine learning to measure eye movements may help track the progression of Parkinson’s disease, a study shows. “NeuraLight’s technology enables us to assess the patient’s neurological status in a sensitive and objective way. The results of this study mark an important…

Gain Therapeutics cleared to start GT-02287 Phase 1 trial in Australia

An ethics committee in Australia has cleared Gain Therapeutics to start a Phase 1 clinical trial testing GT-02287, the company’s experimental oral therapy for Parkinson’s disease associated with mutations in the GBA1 gene. GT-02287 now will become the first treatment candidate discovered with Gain’s proprietary platform, SEE-Tx, to…